Trials / Completed
CompletedNCT03193398
BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy And Safety Study Of BTRX-246040 Administered Once Daily In Patients With Major Depressive Disorder With Or Without Anhedonia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 104 (actual)
- Sponsor
- BlackThorn Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will determine the efficacy, safety, and tolerability of a once-daily (QD) dose of up to 80 mg of BTRX-246040 for 8 weeks in participants with MDD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BTRX-246040 oral capsule(s) | BTRX-246040 administered once daily to patients with MDD for 8 weeks |
| DRUG | Placebo oral capsule(s) | administered once daily to patients with MDD for 8 weeks |
Timeline
- Start date
- 2017-06-12
- Primary completion
- 2018-11-12
- Completion
- 2018-12-12
- First posted
- 2017-06-20
- Last updated
- 2021-05-11
- Results posted
- 2021-05-11
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03193398. Inclusion in this directory is not an endorsement.